6th Conference on Cannabinoids in Medicine and
5th European Workshop on Cannabinoid Research, September 8–10, 2011
A joint meeting of the European Workshop on Cannabinoids and the International Association for Cannabinoid Medicines (IACM)
Programs and Abstracts (PDF): http://www.cannabis-med.org/meeting/Bonn2011/abstractbook.pdf
Sponsors:
- Deutsche Forschungsgemeinschaft
- International Society of Neurochemistry
- Bedrocan
- Almirall Hermal
- Bionorica Ethics
- Echo Pharmaceuticals
- THC Pharm
- Meda Pharmaceuticals
International Association for Cannabinoid Medicines: http://cannabis-med.org
Internet: http://www.bonn2011.org
ORGANIZING COMMITTEE
Co-Chairs
Franjo Grotenhermen
Andreas Zimmer
Members
Manuel Guzman
Roger Pertwee
Ethan Russo
SCIENTIFIC COMMITTEE
Itai Bab
Javier Fernandez-Ruiz
Franjo Grotenhermen
Manuel Guzman
Roger Pertwee
Ethan Russo
Mark Ware
Andreas Zimmer
CONFERENCE PROGRAM
Thursday, September 8
13:00-19:00 Registration
15:00-15:15
Opening and Introduction
15:15-16:00 Plenary Lecture I
Daniele Piomelli
The Endocannabinoid System: New tools lead to new insights
Chair: A. Zimmer
16:00-16:30 COFFEE BREAK
16:30-18:15 Session I - Brain functions
Chair: M. Guzman
16:30-17:00 Ken Mackie
Mechanisms of CB1 receptor desensitization
17:00-17:30 Beat Lutz
Cell type-specific functions of the brain's endocannabinoid system
17:30-17:45 Ana Luisa Terzian
The cross-talk between dopamine and cannabinoid in emotions and cognition: the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors
17:45-18:00 Patrik Roser
Auditory mismatch negativity generation in schizophrenia with and without comorbid cannabis use
18:00-18:15 Miriam Schneider
Social rejection in adolescent rats induces persistent alterations in pain perception and CB1 receptor expression - A new animal model with relevance for borderline personality disorder
18:30-21:00 GET-TOGETHER WITH WINE TASTING
Festsaal (see floor plan)
Friday, September 9
09:00-17:00 Registration
09:00-09:45 Plenary Lecture II
George Kunos
The peripheral endocannabinoid/CB1 receptor system as a novel therapeutic target in obesity/metabolic syndrome
Chair: I. Bab
09:45-10:00 COFFEE BREAK
10:00-11:45 Session II - Metabolism and inflammation
Chair: B. Lutz
10:00 - 10:30 Vincenzo Di Marzo
Targeting the peripheral endocannabinoid system with plant cannabinoids and n-3 polyunsaturated fatty acids to Combat abdominal obesity-associated metabolic disorders
10:30-11:00 Sophie Lotersztajn
Cannabinoid receptors in liver pathophysiology: new insights and therapeutic openings
11:00-11:15 Zvi Vogel
Effects of cannabinoids on microglial gene expression and their role in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis
11:15-11:30 Sabine Steffens
Deficiency of fatty acid amide hydrolase is associated with a vulnerable plaque phenotype in atherosclerosis-prone mice
11:30-11:45 Jose Antonio Martinez Orgado
Cannabidiol reduces hypoxic-ischemic brain damage by modulating excitoxicity, oxidative stress and inflammation. Role of CB2 and 5HT1A receptors
11:45-13:00 LUNCH
13:00-15:00 Session III - Neuroinflammation
Chair: S. Maione
13:00-13:30 Javier Fernandez-Ruiz
Anti-inflammatory and neuroprotective potential of Sativex-like medicines in Huntington's disease: from basic research to clinical studies
13:30-14:00 Andreas Zimmer
CB2 receptor signaling in neuroinflammation
14:00-14:30 Andrea Hohmann
Role of endocannabinoid signalling in the control of pain initiation
14:30-14:45 Onintza Sagredo
Potential exidation of 2- AG by COX-2 enhances malonate toxicity in the striatum: Relevance for cannabinoid treatments in Huntington's Disease
14:45-15:00 Judith Alferink
CB2 signaling is required for susceptibility of cerebral malaria
15:00 -17:00 POSTER SESSION I AND COFFEE BREAK
[IACM General Meeting]
17:00-18:30 Session IV - Translational and preclinical studies
Chair: J. Fernandez-Ruiz
17:00-17:30 Manuel Guzman
Therapeutic potential of cannabinoids as anticancer drugs
17:30 - 18:00 Aron Lichtman
Targeting Endocannabinoid Hydrolytic Enzymes to treat Neuropathic and Inflammatory Pain
18:00-18:15 Evelyn Gaffal
CB1 receptor deficiency in epidermal keratinocytes promotes contact allergic inflammation and delays epidermal barrier repair response
18:15-18:30 Ethan Russo
Cannabidiol and TRPV1: Turning down the heat (and pain)
Saturday, September 10
08:30-12:00 Registration
08:45-10:50 Session V- Bone
Chair: I. Bab
08:45-09:15 Itai Bab
Novel Cannabinoid Skeletal Targets
09:15-09.45 Ruth Ross
Cannabinoids and bone biology: latest developments
09:45-10:05 Sabatino Maione
The expression of TRPV1 channel and ofCB1 vs CB2 cannabinoid receptors is modified in osteoclasts from osteoporotic women
10:05-10:20 Thomas Randau
CB2 receptor expression in human spinal mesenchymal stem cells
from patients with osteoporosis
10:20 - 10:35 Jiirg Gertsch
Osteoclastogenesis inhibition by a novel class of biphenyl-type
cannabinoid CB2 receptor inverse agonists
10:35-10:50 COFFEE BREAK
11:05-12:05 Session VI - Herbal cannabis
Chair: W. Notcutt
10:50-11:20 Roger Pertwee
Phytocannabinoid Pharmacology: New Discoveries and Therapeutic Possibilities
11:20-11:35 Jeffrey Hergenrather
Clinical improvement and reduction of immunosuppressive drug therapy in cannabis treated patients with Crohn's Disease and ulcerative colitis
11:35-11:50 Arno Hazekamp
The medicinal use of cannabis and cannabinoids: an international survey on methods of intake
11:50-12:05 Sarah Martin
Cannabis oils produced by a multiple sclerosis patient reveals the potentials of cannabis when used in its natural form
12:05-13:15 LUNCH
13:15-14:30 POSTER SESSION II
14:30-16:30 Sativex, Nabilone, and Dronabinol
Chair: D. Abrams
14:30-15:00 Philip Robson
Sativex - a clinical overview
15:00-15:30 William Notcutt - Title N.N.
A Retrospective Description of the Use of Nabilone in UK Clinical Practice
15:30-16:00 Tjalling Erkelens
Bedrocan Research and Development - stimulating the development of herbal cannabis based-products
16:00-16:15 Tim Beumer
First in human trial of an oral tablet with A9-THC (Namisol)
16:15-16:30 Franjo Grotenhermen
Practical aspects of a treatment with dronabinol (THC)
16:30-17:00 BUSINESS MEETING
European Workshop on Cannabinoid Research
17:00-18:00 Session VII - Hot topics from the lab and the clinic
Chair: R. Pertwee
17:00-17:15 Stefan Engeli
Circulating endocannabinoids are related to blood pressure in patients with obstructive sleep apnea
17:15-17:30 Attila Olah
Weed against ZIT? Cannabidiol inhibits lipid synthesis of human sebocytes both in vitro and in vivo
17:30-17:45 Linda Klumpers
Demonstrating peripheral restriction ofCB1 antagonist TM 38837 in humans
17:45-18:00 Viktor Rempel
Xanthine derivatives as novel ligands for cannabinoid receptors and the related orphan receptor GPR55
18:00-18:30 Special Presentation
Raphael Mechoulam
Beyond Cannabis and Anandamide
Chair: A. Zimmer
19:30-22:00 CONFERENCE DINNER
POSTER LIST
1 AGE-RELATED CHANGES IN THE ENDOCANNABINOID LEVELS, OXIDATIVE
STRESS AND LYSOSOMAL ACTIVITY IN MICE LACKING CB1 RECEPTOR
A. Piyanova , O. Albayram, K. Michel, R. Buchalla, C. Schwitter, B. Lutz, A. Zimmer, A. Bilkei- Gorzo
2 ROLE OF CANNABINOID 1 RECEPTORS ON HIPPOCAMPAL GABAERGIC NEURONS IN BRAIN AGING
O. Albayram , J. Alferink, A. Piyanova, K. Monory, B.Lutz, A. Zimmer, A. Bilkei-Gorzo
3 MULTITARGET DRUGS AT CB2 RECEPTOR AND BuChE FOR ALZHEIMER
DISEASE
Gonzalez-Naranjo P. , Perez C, Campillo Nuria E., Giron R., Sanchez E., Martin Ml, Gomez- Canas M., Fernandez-Ruiz J., Romero J., and J.A. Paez
4 THE COMBINATION OF D9-THC AND CANNABIDIOL REDUCES THE COGNITIVE IMPAIRMENT IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE
E. Aso , S. Juves, R. Maldonado, I. Ferrer
5 CANNABINOID RECEPTOR 1 (CB1) KNOCK-OUT AFFECTS BIOCHEMICAL
PROCESSING OF THE AMYLOID PRECURSOR PROTEIN (APP) AND LEADS TO A
DECREASE IN COGNITIVE ABILITIES IN A MOUSE MODEL OF ALZHEIMER'S
DISEASE (AD)
C. Hiebel , C. Stumm, R. Hanstein, H. Nagel, M. Purrio, A. Conrad, B. Lutz, C. Behl and A. B. Clement
6 ANXIOLYTIC-LIKE PROPERTIES OF ST4070, A NOVEL, POTENT AND SELECTIVE REVERSIBLE INHIBITOR OF FAAH
M. Maccarrone, E. M. Marco, C. Rapino, A. Caprioli, F. Borsini, G. Laviola and S. Oddi
7 A STRUCTURE-AFFINITY STUDY ON NEW RESORCINOL "HYBRIDS": ROLE OF
THE AMIDE HEAD ON THE CANNABINOID RECEPTOR INTERACTION
A. Brizzi , M. G. Cascio, F. Aiello, A. Ligresti, V. Brizzi, R. G. Pertwee, F. Corelli and V. Di Marzo
8 EFFECTS OF CANNABIDIOL AND OTHER PHYTOCANNABINOIDS ON
SEROTONIN 5-HT 1A RECEPTORS
M. G. Cascio , D. Bolognini, L. A. Stevenson and R. G. Pertwee
9 TONIC INHIBITORY EFFECT OF ENDOCANNABINOIDS ON HUMAN CONNECTIVE TISSUE- AND MUCOSAL- TYPE MAST CELL FUNCTIONS IN SITU VIA CANNABINOID RECEPTOR 1 (CB1) SIGNALING
K. Sugawara , T. Biro, A. Kromminga, D. Tsuruta, B. I Toth, N. Zakany, T. Hundt, V. Emelianov,
B. F. Gibbs, and R. Paus
10 CANNABINOID RECEPTOR TRAFFICKING IN PERIPHERAL IMMUNE CELLS IS TYROSINE PHOSPHATASE-DEPENDENT
J. Kleyer , S. Nicolussi and J. Gertsch
11 FREQUENCY-DEPENDENT MODULATION OF NORADRENERGIC TRANSMISSION BY CANNABINOIDS IN THE RAT PREFRONTAL CORTEX (PFC)
H. Richter , F. M. Teixeira, S. G. Ferreira, F. Goloncser, A. Kittel, A. Kofalvi, B. Sperlagh
12 INTERACTION OF 2-ARACHIDONOYLGLYCEROL WITH THE GABA A RECEPTOR COMPLEX
C. M. van Rijn and E. Willems-van Bree
13 DEFRAGMENTATION OF THE PERIODS OF IMMOBILITY DURING CHRONIC
ADMINISTRATION OF PHYTOCANNABINOIDS IN RATS
C. M. van Rijn , A. Hafkemeijer, M. LA Jongsma and R. J. Glas
14 PROPOFOL AT THERAPEUTIC DOSE IS NOT A HUMAN FATTY ACID AMIDE
HYDROLASE INHIBITOR
C. Jarzimski, M. Karst, A. A. Zoerner, C. Rakers, M. May, M. Suchy, D. Tsikas, J. K. Krauss, D. Scheinichen, J. Jordan, S. Engeli
15 ANTI-INFLAMMATORY EFFECT OF 5-AMINOSALICYLIC ACID ON THE PPARA SIGNALING SYSTEM IN THE HUMAN ULCERATIVE COLITIS
J. Suarez , Y. S. Romero-Zerbo, L. Marquez, F. J. Bermudez-Silva, M. Iglesias, M. Andreu, F. Rodrfguez de Fonseca
16 LIQUID EXTRACTION OF ENDOCANNABINOIDS WITH TOLUENE REDUCES
MATRIX EFFECTS AND TRANS-ACYLATION OF 2-ARACHIDONOYL GLYCEROL
TO 1-ARACHIDONOYL GLYCEROL
A. A. Zoerner , S. Batkai, S. Engeli, M. T. Suchy, J. Jordan, D. Tsikas
17 SYSTEMATIC CHARACTERIZATION OF ENDOCANNABINOID MICRODIALYSIS
A. A Zoerner , C. Rakers, S. Engeli, S. Batkai, M. May, J. Jordan, D. Tsikas
18 DESIGN AND SYNTHESIS OF NEW QUINOLONE-7-SUBSTITUTED-3-
CARBOXAMIDES AS POTENTIAL CB1 SELECTIVE LIGANDS
M. De Rosa , S. Pasquini, C. Mugnaini, A. Brizzi, F. Corelli, A. Ligresti and V. Di Marzo
19 IMMUNOAFFINITY CHARACTERIZATION OF PEPTIDE ENDOCANNABINOIDS
IDENTIFICATION OF N-TERMINAL EXTENDED PRECURSORS
M. Bauer and J. Gertsch
20a SYNTHESIS OF 1,3,7-TRISUBSTITUTED XANTHINE DERIVATIVES AS LIGANDS
FOR CANNABINOID AND RELATED GPCRS
D. Horn , C. E. Muller
20b XANTHINE DERIVATIVES AS NOVEL LIGANDS FOR CANNABINOID RECEPORS
AND THE RELATED ORPHAN RECEPTOR GPR55
V. Rempel , D. Horn, C. E. Muller
21 DEVELOPMENT OF POTENT ENDOCANNABINOID REUPTAKE INHIBITORS FROM
A PLANT DERIVED A/-ISOBUTYLAMIDE SCAFFOLD
S. Nicolussi, A. Chicca, M. Soeberdt, J. Gertsch
22 THE C385A MISSENSE VARIANT MODULATES ACUTE STRESS RESPONSE IN
HEALTHY HUMANS
A. Dlugos , E. Childs, A. A. Palmer and H. de Wit
23 A MOUSE LINE FOR CELL TYPE-SPECIFIC RESCUE FROM CB1 RECEPTOR
DEFICIENCY
S. Ruhle , G. Marsicano, B. Lutz
24 GENERATION OF CB2 RECEPTOR HUMANIZED MICE
B. Gennequin , D.-M. Otte, X. Miro, M. Karsak, A. M. Zimmer, A. Zimmer
25 GENERATION OF CONDITIONAL KNOCK OUT MICE FOR DIACYLGLYCEROL
LIPASE a AND (3
S. Ternes, D.-M. Otte, A.M. Zimmer, J. Schmidt, C. Hamsch, A. Zimmer
26 EVIDENCE SUPPORTING THE EXISTENCE OF AN ENDOCANNABOID
MEMBRANE TRANSPORTER INVOLVED IN CELLULAR AEA AND 2-AG UPTAKE
A. Chicca , J. Marazzi, S. Nicolussi and J. Gertsch
27 AMINO ACIDS D2.63 AND K373 ARE IMPORTANT FOR MAINTAINING THE CB1R
BINDING POCKET, WHILE RESIDUES K3.28 AND S1.39 ARE INVOLVED IN
SELECTIVE LIGAND RECOGNITION
J. P. Marcu , A. Kapur, M. Trznadel, P. H. Reggio, M. E. Abood
28 DEFINITION OF THE CELLULAR SOURCE OF ELEVATED 2-AG LEVELS IN THE
LIVER AND ANALYSIS OF 2-AG INDUCED CELL DEATH IN HEPATIC STELLATE
CELLS
A. Wojtalla , M. V. Singer, T. Sauerbruch, A. Zimmer, S. V. Siegmund
29 REGULATION OF TYPE 1 CANNABINOID RECEPTORS AND MU OPIOID
RECEPTORS BY MICRORNA AND POSSIBLE CONSEQUENCES ON DRUG
TOLERANCE
C. Borner , J. Kraus, E. Martella, V. Hollt
30 ACUTE AND CHRONIC CANNABINOID TREATMENT DIFFERENTLY AFFECT
ALCOHOL INTAKE IN PUBERTAL AND ADULT RATS
C. M. Friemel , R. Spanagel, M. Schneider
31 INVOLVEMENT OF THE ECB SYSTEM IN HEDONIC REWARD PROCESSING -
MEASURED BY THE PLEASURE ATTENUATED STARTLE PARADIGM
M. Schneider , A. Zimmer, C. Friemel, T. Brand
32 CANNABIDIOL ATTENUATES SOCIAL ISOLATION-INDUCED AGGRESSION IN
MICE
F. V. Gomes , S. F. Lisboa and F. S. Guimaraes
33 DIAGNOSIS OF MAJOR DEPRESSION USING ETHANOLAMINE PHOSPHATE
(EAP): POSSIBLE APPLICATION FOR DEVELOPMENT OF ANTIDEPRESSANT
MANIPULATING THE ENDOCANNABINOID SYSTEM
Y. Ohashi, K. Shinoda, H. Sato, K. Sasaki, H. Yamamoto, T. Ishikawa, N. Kawamura
34 DEMONSTRATING PERIPHERAL RESTRICTION OF NOVEL CANNABINOID CB1
ANTAGONIST TM38837 BY EVALUATING FOR EXPRESSION OF CONDITIONED
FEAR IN MICE
V. Micale , P. K. Norregaard and C. T. Wotjak
35 EFFECTS ON FEAR AND ANXIETY OF AAV VECTOR-MEDIATED
OVEREXPRESSION OF MAGL IN GLUTAMATERGIC NEURONS OF THE
BASOLATERAL AMYGDALA
F. Remmers , S. Guggenhuber, S. Ruehle, B. Lutz
36 AAV-MEDIATED OVEREXPRESSION OF THE CB1 RECEPTOR IN THE MPFC OF
ADULT RATS ALTERS COGNITIVE AND EMOTIONAL BEHAVIOR
A. Goepfrich , M. Klugmann, C. M. Friemel, M. Schneider
37 ACUTE AND CHRONIC EFFECTS OF CANNABINOIDS ON THE BEHAVIOUR OF
ZEBRAFISH EMBRYOS
T. Akhtar , S. Ali, H. Rashidi, F. van der Kooy, R. Verpoorte and M. K. Richardson
38 THE IMPACT OF THE ENDOCANNABINOID SYSTEM ON SOUND LOCALISATION
B. Trattner , S. Berner, B. Grothe and L. Kunz
39 CANNABINOID POTENTIATION OF GLYCINE RECEPTORS CONTRIBUTES TO
CANNABIS-INDUCED ANALGESIA
L. Zhang and W. Xiong
40 THE ROLE OF CB2 RECEPTORS IN MODULATION OF INFLAMMATORY PAIN
I. Racz , A. Markert, J. Gertsch, A. Zimmer
41 TARGETING NEUROPATHIC PAIN THROUGH ENDOCANNABINOID RECEPTOR
SIGNALING
A.-L. Klauke , I. Racz, A. Markert, J. Gertsch, A. Zimmer
42 CB2 RECEPTOR MEDIATES PHAGOCYTOSIS AND SCAR FORMATION AFTER
MYOCARDIAL INFARCTION IN MURINE HEART
G. P. Duerr , T. Heuft, G. Suchan, T. Klaas, A. Welz, A. Zimmer, B. K. Fleischmann, O. Dewald
43 EFFECTS OF HIGH GLUCOSE AND INSULIN ON VASORELAXATION TO
ANANDAMIDE
W.-S. Vanessa Ho
44 THE ENDOCANNABINOID ANANDAMIDE MEDIATES HYPOXIC PULMONARY
VASOCONSTRICTION VIA FATTY ACID AMIDE HYDROLASE (FAAH)
METABOLIZATION PRODUCTS
D. Wenzel , M. Matthey, R. Buchalla, C. Schwitter, B. Lutz, A. Zimmer, B. K. Fleischmann
45 STRATEGIC LOCALIZATION OF TRPV1 EXPRESSING CELLS IN THE BRAIN
VASCULAR SYSTEM
M. Tauchi and R. Kollmar
46 SINGLE DOSE ADMINISTRATION OF CANNABIDIOL AFTER BRAIN HYPOXIA-
ISCHEMIA AFFORDS LONG-LASTING NEUROPROTECTION IN NEWBORN RATS
Pazos MR, Cinquina V, Gomez A, Layunta R, Mohamed N, Martinez-Orgado J.
47 ENDOCANNABINOID CONTENT IN FETAL BOVINE SERA - UNEXPECTED
EFFECTS ON MONONUCLEAR CELLS AND OSTEOCLASTOGENESIS
J. Marazzi , J. Kleyer, J. M. Viveros Paredes, J. Gertsch
48 OSTEOCLASTOGENESIS INHIBITION BY A NOVEL CLASS OF BIPHENYL-TYPE CANNABINOID CB2 RECEPTOR INVERSE AGONISTS
J. M. Viveros Paredes, W. Schuehly, J. Kleyer, A. Huefner, S. Anavi-Goffer, S. Raduner, K.-H. Altmann and J. Gertsch
49 DO CB1 CANNABINOID RECEPTORS REGULATE INSULIN SIGNALLING IN RAT PRIMARY SKELETAL MUSCLE CELLS?
M. Haddad , K. Tsintzas, S.P.H. Alexander and A.J. Bennett
50 CB1 CANNABINOID RECEPTOR ANTAGONISM INHIBITS BALLOON-INDUCED NEOINTIMA FORMATION IN ATHEROSCLEROTIC MICE
F. Molica , F. Burger, C. M. Matter, A. Thomas, C. Staub, A. Zimmer, B. Cravatt, P. Pacher, S. Steffens
51 THE ENDOCANNABINOID SYSTEM SHOWS DIFFERENT ALTERATIONS IN IN
VITRO AND IN VIVO MODELS OF HUNTINGTON'S DISEASE
M. Maccarrone, M. Bari, N. Battista, M. Valenza, M. Malaponti, G. Catanzaro, C. Di Pancrazio, N. Mastrangelo, D. Centonze, A. Finazzi-Agro, E. Cattaneo and S. Oddi
52 DISEASE-MODIFYING EFFECTS OF WIN55.212-2 IN A MODEL OF MULTIPLE
SCLEROSIS IN MICE: ROLE OF CB1 AND CB2 RECEPTORS
E. de Lago , M. Moreno-Martet, C. Rodrfguez-Cueto, C. Palomo-Garo, C. Garcia, M. Gomez-Ruiz, J. A. Ramos and J. Fernandez-Ruiz
53 EFFECTS OF CANNABIS USE ON SOME IMMUNE PARAMETERS IN PATIENTS
WITH MULTIPLE SCLEROSIS
M. Sexton and N. Stella
54 CANNABIDIOL, NON-PSYCHOACTIVE CANNABINOID, AMELIORATES CLINICAL SYMPTOMS AND DECREASES MICROGLIAL ACTIVATION IN MOG-TREATED MICE
E. Kozela , N. Lev, A. Juknat, M. Pietr, N. Rimmerman, R. Levy, Z. Vogel
55 A NOVEL 3D MODEL OF THE HUMAN CANNABINOID RECEPTOR 2 IN ITS ACTIVE STATE HELPS TO DEVELOP NEW RADIOTRACERS FOR POSITRON EMISSION TOMOGRAPHY (PET)
R. Gunther , W. Deuther-Conrad, S. Fischer, T. Ruhl, J. Steinbach, P. Brust
56 18 FLUORINE-LABELED NITROGEN HETEROCYCLIC DERIVATIVES AS NEW
CANDIDATE FOR CANNABINOID CB2 RECEPTOR PET IMAGING
F. Castelli , G. Saccomanni, S. Bertini, S. Del Carlo, V. Di Marzo, V. Lucchesi, C. Manera, G.
Pascali, P. Salvadori, M. Macchia
57 DEVELOPMENT OF AN ULTRA SENSITIVE LC-MS/MS METHOD FOR THE
SIMULTANEOUS DETERMINATION OF A9-TETRAHYDROCANNABINOL AND ONE OF ITS MAJOR METABOLITES A9-(11-OH) TETRAHYDROCANNABINOL IN HUMAN PLASMA
M. Boterman , T. Beumer, F. Oostebring, A. Meijer and E. Oosting
58 DEVELOPMENT, VALIDATION AND USE OF A LC-MS/MS METHOD TO ASSAY
FAAH ACTIVITY IN BIOLOGICAL SAMPLES
C. Rakers , A. A. Zoerner, S. Batkai, S. Engeli, J. Jordan, D. Tsikas
59 A NEW TLC DENSITOMETRY METHOD IN A KIT-FORMAT FOR COMPLETE
SEPARATION AND VISUALISATION OF ALL CANNABINOIDS IN CANNABIS
SPECIES
R.J. Glas
60 INTESTINAL N-ACYLETHANOLAMINE LEVELS ARE DOWN-REGULATED IN BOTH MICE AND RATS BY SENSING OF DIETARY FAT
T. A. Diep , A. N. Madsen, N. Wellner, B. Hoist and H. S. Hansen
61 CIRCADIAN RHYTHM OF BLOOD ENDOCANNABINOIDS - IS FOOD INTAKE THE KEY TRIGGER?
M. May , S. Batkai, A. A. Zoerner, D. Tsikas, J. Jordan, S. Engeli
62 STUDIES ON THE ANORECTIC EFFECT OF N-ACYLPHOSPHATIDYLETHANO-
LAMINE AND PHOSPHATIDYLETHANOLAMINE IN MICE
N. Wellner , K. Tsuboi, A. N. Madsen, B. Hoist, T. A. Diep, M. Nakao, A. Tokumura, M. P. Burns, D. G. Deutsch, N. Ueda and H. S. Hansen
63 EFFECTS OF CHRONIC ADMINISTRATION OF CANNABINOID RECEPTOR
INVERSE AGONIST (AM 251) ON THE FOOD INTAKE, BODY WEIGHT GAIN AND
OXYGEN CONSUMPTION IN OBESE ZUCKER RATS
I. Merroun , J. M. Porres, G. Urbano, P. Aranda, J. Llopis, M. Errami and M. Lopez-Jurado
64 METABOLIC FINGERPRINTING OF CANNABIS SATIVA L, CANNABINOIDS AND TERPENOIDS FOR CHEMOTAXONOMIC AND DRUG STANDARDIZATION
PURPOSES
J. T. Fischedick , A. Hazekamp, T. Erkelens, Y. H. Choi, R. Verpoorte
65 CANNABINOID RECEPTOR 1 IN HODGKIN LYMPHOMA AND B-CELL NON-HODGKIN LYMPHOMA ENTITIES: EXPRESSION AND FUNCTIONAL RELEVANCE FOR SURVIVAL OF TUMOR CELLS
A. H. Benz , C. Renne, M. Koch, E. Maronde, S. Kallendrusch, B. Rengstl, S. Newrzela, S.
Hartmann, M.-L. Hansmann and F. Dehghani
66 DEVELOPMENT OF CB2 SELECTIVE CANNABINOID RECEPTOR LIGANDS AS
POTENTIAL ANTITUMOR AGENTS
V. Lucchesi , F. Castelli, C. Manera, S. Bertini, S. Del Carlo, A. Ligresti, A. M. Malfitano, G. Saccomanni, V. Di Marzo, M. Bifulco, M. Macchia
67 BASALIOMA TREATMENT WITH INTRATUMORAL INJECTIONS OF A CANNABIS-OIL EXTRACT: A SINGLE-CASE STUDY
J. Pedraza-Valiente
68 IMPROVEMENT OF CLONAL PROPAGATION OF CANNABIS SATIVA L. FOR
PHARMACEUTICAL PRODUCTION
S. Beguerie , S. Casano, G. Grassi
69 CLONING OF PHARMACEUTICAL CANNABIS THROUGH AN AEROPONIC
PROPAGATION SYSTEM
S. Beguerie , S. Casano, G. Grassi
70 ESTIMATION OF USABLE BIOMASS YIELD OF OUTDOOR CULTIVATED CANNABIS SATIVA L. PLANTS
Z. Mehmedic , S. Chandra, H. Lata, I. A. Khan and M. A. ElSohly
71 A QUESTIONNAIRE SURVEY OF PATIENTS PRESCRIBED SATIVEX AS
UNLICENSED MEDICINE
Notcutt, W.
72 GLYCINE RECEPTORS, A NEW TARGET FOR MEDICAL MARIJUANA
L. Zhang and W. Xiong
73 USE OF MEDICINAL CANNABIS IN THE NETHERLANDS
L. Wiinkoop , A. Hazekamp, R. Heerdink
74 MEDICAL CANNABIS USE IN POST-TRAUMATIC STRESS DISORDER: A
NATURALISTIC OBSERVATIONAL STUDY
75 PSYCHOSOCIAL STRESS MODULATES CIRCULATING ANANDAMIDE AND
OTHER N-ACYLETHANOLAMINES IN HEALTHY HUMANS
A. Dluqos , E. Childs, K. Stuhr, C. Hillard, H. de Wit
76 THE EFFECT OF CANNABIS INTOXICATION ON EGO EQUILIBRIUM:
INVESTIGATING THE ACUTE DEVELOPMENTAL IMPACT OF AN ALTERED STATE OF CONSCIOUSNESS
M. Metzqer
77 THE SOCIAL AND BIOETHICAL ASPECTS OF USE OF MEDICINAL CANNABIS IN CROATIA
M. Gold , S. Kantar, K. Svrznjak
78 EVALUATION OF A NEW PLATFORM TO ADMINISTER CANNABINOIDS BY
INHALING: MINIVAP® PORTABLE VAPORIZER
J. Fernandez , A. Hazehamp
79 INTOXICATIONS FOLLOWING RECREATIONAL USE OF HERBAL PRODUCTS
CONTAINING SYNTHETIC CANNABINOIDS
Bela Szabo , Volker Auwarter, Stefan Kneisel and Maren Hermanns-Clausen
Abstract book online:
- Internet Archive: http://www.archive.org/details/CannabinoidConference2011
ORGANIZING COMMITTEE
Co-Chairs
Franjo Grotenhermen
Andreas Zimmer
Members
Manuel Guzman
Roger Pertwee
Ethan Russo
SCIENTIFIC COMMITTEE
Itai Bab
Javier Fernandez-Ruiz
Franjo Grotenhermen
Manuel Guzman
Roger Pertwee
Ethan Russo
Mark Ware
Andreas Zimmer
CONFERENCE PROGRAM
Thursday, September 8
13:00-19:00 Registration
15:00-15:15
Opening and Introduction
15:15-16:00 Plenary Lecture I
Daniele Piomelli
The Endocannabinoid System: New tools lead to new insights
Chair: A. Zimmer
16:00-16:30 COFFEE BREAK
16:30-18:15 Session I - Brain functions
Chair: M. Guzman
16:30-17:00 Ken Mackie
Mechanisms of CB1 receptor desensitization
17:00-17:30 Beat Lutz
Cell type-specific functions of the brain's endocannabinoid system
17:30-17:45 Ana Luisa Terzian
The cross-talk between dopamine and cannabinoid in emotions and cognition: the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors
17:45-18:00 Patrik Roser
Auditory mismatch negativity generation in schizophrenia with and without comorbid cannabis use
18:00-18:15 Miriam Schneider
Social rejection in adolescent rats induces persistent alterations in pain perception and CB1 receptor expression - A new animal model with relevance for borderline personality disorder
18:30-21:00 GET-TOGETHER WITH WINE TASTING
Festsaal (see floor plan)
Friday, September 9
09:00-17:00 Registration
09:00-09:45 Plenary Lecture II
George Kunos
The peripheral endocannabinoid/CB1 receptor system as a novel therapeutic target in obesity/metabolic syndrome
Chair: I. Bab
09:45-10:00 COFFEE BREAK
10:00-11:45 Session II - Metabolism and inflammation
Chair: B. Lutz
10:00 - 10:30 Vincenzo Di Marzo
Targeting the peripheral endocannabinoid system with plant cannabinoids and n-3 polyunsaturated fatty acids to Combat abdominal obesity-associated metabolic disorders
10:30-11:00 Sophie Lotersztajn
Cannabinoid receptors in liver pathophysiology: new insights and therapeutic openings
11:00-11:15 Zvi Vogel
Effects of cannabinoids on microglial gene expression and their role in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis
11:15-11:30 Sabine Steffens
Deficiency of fatty acid amide hydrolase is associated with a vulnerable plaque phenotype in atherosclerosis-prone mice
11:30-11:45 Jose Antonio Martinez Orgado
Cannabidiol reduces hypoxic-ischemic brain damage by modulating excitoxicity, oxidative stress and inflammation. Role of CB2 and 5HT1A receptors
11:45-13:00 LUNCH
13:00-15:00 Session III - Neuroinflammation
Chair: S. Maione
13:00-13:30 Javier Fernandez-Ruiz
Anti-inflammatory and neuroprotective potential of Sativex-like medicines in Huntington's disease: from basic research to clinical studies
13:30-14:00 Andreas Zimmer
CB2 receptor signaling in neuroinflammation
14:00-14:30 Andrea Hohmann
Role of endocannabinoid signalling in the control of pain initiation
14:30-14:45 Onintza Sagredo
Potential exidation of 2- AG by COX-2 enhances malonate toxicity in the striatum: Relevance for cannabinoid treatments in Huntington's Disease
14:45-15:00 Judith Alferink
CB2 signaling is required for susceptibility of cerebral malaria
15:00 -17:00 POSTER SESSION I AND COFFEE BREAK
[IACM General Meeting]
17:00-18:30 Session IV - Translational and preclinical studies
Chair: J. Fernandez-Ruiz
17:00-17:30 Manuel Guzman
Therapeutic potential of cannabinoids as anticancer drugs
17:30 - 18:00 Aron Lichtman
Targeting Endocannabinoid Hydrolytic Enzymes to treat Neuropathic and Inflammatory Pain
18:00-18:15 Evelyn Gaffal
CB1 receptor deficiency in epidermal keratinocytes promotes contact allergic inflammation and delays epidermal barrier repair response
18:15-18:30 Ethan Russo
Cannabidiol and TRPV1: Turning down the heat (and pain)
Saturday, September 10
08:30-12:00 Registration
08:45-10:50 Session V- Bone
Chair: I. Bab
08:45-09:15 Itai Bab
Novel Cannabinoid Skeletal Targets
09:15-09.45 Ruth Ross
Cannabinoids and bone biology: latest developments
09:45-10:05 Sabatino Maione
The expression of TRPV1 channel and ofCB1 vs CB2 cannabinoid receptors is modified in osteoclasts from osteoporotic women
10:05-10:20 Thomas Randau
CB2 receptor expression in human spinal mesenchymal stem cells
from patients with osteoporosis
10:20 - 10:35 Jiirg Gertsch
Osteoclastogenesis inhibition by a novel class of biphenyl-type
cannabinoid CB2 receptor inverse agonists
10:35-10:50 COFFEE BREAK
11:05-12:05 Session VI - Herbal cannabis
Chair: W. Notcutt
10:50-11:20 Roger Pertwee
Phytocannabinoid Pharmacology: New Discoveries and Therapeutic Possibilities
11:20-11:35 Jeffrey Hergenrather
Clinical improvement and reduction of immunosuppressive drug therapy in cannabis treated patients with Crohn's Disease and ulcerative colitis
11:35-11:50 Arno Hazekamp
The medicinal use of cannabis and cannabinoids: an international survey on methods of intake
11:50-12:05 Sarah Martin
Cannabis oils produced by a multiple sclerosis patient reveals the potentials of cannabis when used in its natural form
12:05-13:15 LUNCH
13:15-14:30 POSTER SESSION II
14:30-16:30 Sativex, Nabilone, and Dronabinol
Chair: D. Abrams
14:30-15:00 Philip Robson
Sativex - a clinical overview
15:00-15:30 William Notcutt - Title N.N.
A Retrospective Description of the Use of Nabilone in UK Clinical Practice
15:30-16:00 Tjalling Erkelens
Bedrocan Research and Development - stimulating the development of herbal cannabis based-products
16:00-16:15 Tim Beumer
First in human trial of an oral tablet with A9-THC (Namisol)
16:15-16:30 Franjo Grotenhermen
Practical aspects of a treatment with dronabinol (THC)
16:30-17:00 BUSINESS MEETING
European Workshop on Cannabinoid Research
17:00-18:00 Session VII - Hot topics from the lab and the clinic
Chair: R. Pertwee
17:00-17:15 Stefan Engeli
Circulating endocannabinoids are related to blood pressure in patients with obstructive sleep apnea
17:15-17:30 Attila Olah
Weed against ZIT? Cannabidiol inhibits lipid synthesis of human sebocytes both in vitro and in vivo
17:30-17:45 Linda Klumpers
Demonstrating peripheral restriction ofCB1 antagonist TM 38837 in humans
17:45-18:00 Viktor Rempel
Xanthine derivatives as novel ligands for cannabinoid receptors and the related orphan receptor GPR55
18:00-18:30 Special Presentation
Raphael Mechoulam
Beyond Cannabis and Anandamide
Chair: A. Zimmer
19:30-22:00 CONFERENCE DINNER
POSTER LIST
1 AGE-RELATED CHANGES IN THE ENDOCANNABINOID LEVELS, OXIDATIVE
STRESS AND LYSOSOMAL ACTIVITY IN MICE LACKING CB1 RECEPTOR
A. Piyanova , O. Albayram, K. Michel, R. Buchalla, C. Schwitter, B. Lutz, A. Zimmer, A. Bilkei- Gorzo
2 ROLE OF CANNABINOID 1 RECEPTORS ON HIPPOCAMPAL GABAERGIC NEURONS IN BRAIN AGING
O. Albayram , J. Alferink, A. Piyanova, K. Monory, B.Lutz, A. Zimmer, A. Bilkei-Gorzo
3 MULTITARGET DRUGS AT CB2 RECEPTOR AND BuChE FOR ALZHEIMER
DISEASE
Gonzalez-Naranjo P. , Perez C, Campillo Nuria E., Giron R., Sanchez E., Martin Ml, Gomez- Canas M., Fernandez-Ruiz J., Romero J., and J.A. Paez
4 THE COMBINATION OF D9-THC AND CANNABIDIOL REDUCES THE COGNITIVE IMPAIRMENT IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE
E. Aso , S. Juves, R. Maldonado, I. Ferrer
5 CANNABINOID RECEPTOR 1 (CB1) KNOCK-OUT AFFECTS BIOCHEMICAL
PROCESSING OF THE AMYLOID PRECURSOR PROTEIN (APP) AND LEADS TO A
DECREASE IN COGNITIVE ABILITIES IN A MOUSE MODEL OF ALZHEIMER'S
DISEASE (AD)
C. Hiebel , C. Stumm, R. Hanstein, H. Nagel, M. Purrio, A. Conrad, B. Lutz, C. Behl and A. B. Clement
6 ANXIOLYTIC-LIKE PROPERTIES OF ST4070, A NOVEL, POTENT AND SELECTIVE REVERSIBLE INHIBITOR OF FAAH
M. Maccarrone, E. M. Marco, C. Rapino, A. Caprioli, F. Borsini, G. Laviola and S. Oddi
7 A STRUCTURE-AFFINITY STUDY ON NEW RESORCINOL "HYBRIDS": ROLE OF
THE AMIDE HEAD ON THE CANNABINOID RECEPTOR INTERACTION
A. Brizzi , M. G. Cascio, F. Aiello, A. Ligresti, V. Brizzi, R. G. Pertwee, F. Corelli and V. Di Marzo
8 EFFECTS OF CANNABIDIOL AND OTHER PHYTOCANNABINOIDS ON
SEROTONIN 5-HT 1A RECEPTORS
M. G. Cascio , D. Bolognini, L. A. Stevenson and R. G. Pertwee
9 TONIC INHIBITORY EFFECT OF ENDOCANNABINOIDS ON HUMAN CONNECTIVE TISSUE- AND MUCOSAL- TYPE MAST CELL FUNCTIONS IN SITU VIA CANNABINOID RECEPTOR 1 (CB1) SIGNALING
K. Sugawara , T. Biro, A. Kromminga, D. Tsuruta, B. I Toth, N. Zakany, T. Hundt, V. Emelianov,
B. F. Gibbs, and R. Paus
10 CANNABINOID RECEPTOR TRAFFICKING IN PERIPHERAL IMMUNE CELLS IS TYROSINE PHOSPHATASE-DEPENDENT
J. Kleyer , S. Nicolussi and J. Gertsch
11 FREQUENCY-DEPENDENT MODULATION OF NORADRENERGIC TRANSMISSION BY CANNABINOIDS IN THE RAT PREFRONTAL CORTEX (PFC)
H. Richter , F. M. Teixeira, S. G. Ferreira, F. Goloncser, A. Kittel, A. Kofalvi, B. Sperlagh
12 INTERACTION OF 2-ARACHIDONOYLGLYCEROL WITH THE GABA A RECEPTOR COMPLEX
C. M. van Rijn and E. Willems-van Bree
13 DEFRAGMENTATION OF THE PERIODS OF IMMOBILITY DURING CHRONIC
ADMINISTRATION OF PHYTOCANNABINOIDS IN RATS
C. M. van Rijn , A. Hafkemeijer, M. LA Jongsma and R. J. Glas
14 PROPOFOL AT THERAPEUTIC DOSE IS NOT A HUMAN FATTY ACID AMIDE
HYDROLASE INHIBITOR
C. Jarzimski, M. Karst, A. A. Zoerner, C. Rakers, M. May, M. Suchy, D. Tsikas, J. K. Krauss, D. Scheinichen, J. Jordan, S. Engeli
15 ANTI-INFLAMMATORY EFFECT OF 5-AMINOSALICYLIC ACID ON THE PPARA SIGNALING SYSTEM IN THE HUMAN ULCERATIVE COLITIS
J. Suarez , Y. S. Romero-Zerbo, L. Marquez, F. J. Bermudez-Silva, M. Iglesias, M. Andreu, F. Rodrfguez de Fonseca
16 LIQUID EXTRACTION OF ENDOCANNABINOIDS WITH TOLUENE REDUCES
MATRIX EFFECTS AND TRANS-ACYLATION OF 2-ARACHIDONOYL GLYCEROL
TO 1-ARACHIDONOYL GLYCEROL
A. A. Zoerner , S. Batkai, S. Engeli, M. T. Suchy, J. Jordan, D. Tsikas
17 SYSTEMATIC CHARACTERIZATION OF ENDOCANNABINOID MICRODIALYSIS
A. A Zoerner , C. Rakers, S. Engeli, S. Batkai, M. May, J. Jordan, D. Tsikas
18 DESIGN AND SYNTHESIS OF NEW QUINOLONE-7-SUBSTITUTED-3-
CARBOXAMIDES AS POTENTIAL CB1 SELECTIVE LIGANDS
M. De Rosa , S. Pasquini, C. Mugnaini, A. Brizzi, F. Corelli, A. Ligresti and V. Di Marzo
19 IMMUNOAFFINITY CHARACTERIZATION OF PEPTIDE ENDOCANNABINOIDS
IDENTIFICATION OF N-TERMINAL EXTENDED PRECURSORS
M. Bauer and J. Gertsch
20a SYNTHESIS OF 1,3,7-TRISUBSTITUTED XANTHINE DERIVATIVES AS LIGANDS
FOR CANNABINOID AND RELATED GPCRS
D. Horn , C. E. Muller
20b XANTHINE DERIVATIVES AS NOVEL LIGANDS FOR CANNABINOID RECEPORS
AND THE RELATED ORPHAN RECEPTOR GPR55
V. Rempel , D. Horn, C. E. Muller
21 DEVELOPMENT OF POTENT ENDOCANNABINOID REUPTAKE INHIBITORS FROM
A PLANT DERIVED A/-ISOBUTYLAMIDE SCAFFOLD
S. Nicolussi, A. Chicca, M. Soeberdt, J. Gertsch
22 THE C385A MISSENSE VARIANT MODULATES ACUTE STRESS RESPONSE IN
HEALTHY HUMANS
A. Dlugos , E. Childs, A. A. Palmer and H. de Wit
23 A MOUSE LINE FOR CELL TYPE-SPECIFIC RESCUE FROM CB1 RECEPTOR
DEFICIENCY
S. Ruhle , G. Marsicano, B. Lutz
24 GENERATION OF CB2 RECEPTOR HUMANIZED MICE
B. Gennequin , D.-M. Otte, X. Miro, M. Karsak, A. M. Zimmer, A. Zimmer
25 GENERATION OF CONDITIONAL KNOCK OUT MICE FOR DIACYLGLYCEROL
LIPASE a AND (3
S. Ternes, D.-M. Otte, A.M. Zimmer, J. Schmidt, C. Hamsch, A. Zimmer
26 EVIDENCE SUPPORTING THE EXISTENCE OF AN ENDOCANNABOID
MEMBRANE TRANSPORTER INVOLVED IN CELLULAR AEA AND 2-AG UPTAKE
A. Chicca , J. Marazzi, S. Nicolussi and J. Gertsch
27 AMINO ACIDS D2.63 AND K373 ARE IMPORTANT FOR MAINTAINING THE CB1R
BINDING POCKET, WHILE RESIDUES K3.28 AND S1.39 ARE INVOLVED IN
SELECTIVE LIGAND RECOGNITION
J. P. Marcu , A. Kapur, M. Trznadel, P. H. Reggio, M. E. Abood
28 DEFINITION OF THE CELLULAR SOURCE OF ELEVATED 2-AG LEVELS IN THE
LIVER AND ANALYSIS OF 2-AG INDUCED CELL DEATH IN HEPATIC STELLATE
CELLS
A. Wojtalla , M. V. Singer, T. Sauerbruch, A. Zimmer, S. V. Siegmund
29 REGULATION OF TYPE 1 CANNABINOID RECEPTORS AND MU OPIOID
RECEPTORS BY MICRORNA AND POSSIBLE CONSEQUENCES ON DRUG
TOLERANCE
C. Borner , J. Kraus, E. Martella, V. Hollt
30 ACUTE AND CHRONIC CANNABINOID TREATMENT DIFFERENTLY AFFECT
ALCOHOL INTAKE IN PUBERTAL AND ADULT RATS
C. M. Friemel , R. Spanagel, M. Schneider
31 INVOLVEMENT OF THE ECB SYSTEM IN HEDONIC REWARD PROCESSING -
MEASURED BY THE PLEASURE ATTENUATED STARTLE PARADIGM
M. Schneider , A. Zimmer, C. Friemel, T. Brand
32 CANNABIDIOL ATTENUATES SOCIAL ISOLATION-INDUCED AGGRESSION IN
MICE
F. V. Gomes , S. F. Lisboa and F. S. Guimaraes
33 DIAGNOSIS OF MAJOR DEPRESSION USING ETHANOLAMINE PHOSPHATE
(EAP): POSSIBLE APPLICATION FOR DEVELOPMENT OF ANTIDEPRESSANT
MANIPULATING THE ENDOCANNABINOID SYSTEM
Y. Ohashi, K. Shinoda, H. Sato, K. Sasaki, H. Yamamoto, T. Ishikawa, N. Kawamura
34 DEMONSTRATING PERIPHERAL RESTRICTION OF NOVEL CANNABINOID CB1
ANTAGONIST TM38837 BY EVALUATING FOR EXPRESSION OF CONDITIONED
FEAR IN MICE
V. Micale , P. K. Norregaard and C. T. Wotjak
35 EFFECTS ON FEAR AND ANXIETY OF AAV VECTOR-MEDIATED
OVEREXPRESSION OF MAGL IN GLUTAMATERGIC NEURONS OF THE
BASOLATERAL AMYGDALA
F. Remmers , S. Guggenhuber, S. Ruehle, B. Lutz
36 AAV-MEDIATED OVEREXPRESSION OF THE CB1 RECEPTOR IN THE MPFC OF
ADULT RATS ALTERS COGNITIVE AND EMOTIONAL BEHAVIOR
A. Goepfrich , M. Klugmann, C. M. Friemel, M. Schneider
37 ACUTE AND CHRONIC EFFECTS OF CANNABINOIDS ON THE BEHAVIOUR OF
ZEBRAFISH EMBRYOS
T. Akhtar , S. Ali, H. Rashidi, F. van der Kooy, R. Verpoorte and M. K. Richardson
38 THE IMPACT OF THE ENDOCANNABINOID SYSTEM ON SOUND LOCALISATION
B. Trattner , S. Berner, B. Grothe and L. Kunz
39 CANNABINOID POTENTIATION OF GLYCINE RECEPTORS CONTRIBUTES TO
CANNABIS-INDUCED ANALGESIA
L. Zhang and W. Xiong
40 THE ROLE OF CB2 RECEPTORS IN MODULATION OF INFLAMMATORY PAIN
I. Racz , A. Markert, J. Gertsch, A. Zimmer
41 TARGETING NEUROPATHIC PAIN THROUGH ENDOCANNABINOID RECEPTOR
SIGNALING
A.-L. Klauke , I. Racz, A. Markert, J. Gertsch, A. Zimmer
42 CB2 RECEPTOR MEDIATES PHAGOCYTOSIS AND SCAR FORMATION AFTER
MYOCARDIAL INFARCTION IN MURINE HEART
G. P. Duerr , T. Heuft, G. Suchan, T. Klaas, A. Welz, A. Zimmer, B. K. Fleischmann, O. Dewald
43 EFFECTS OF HIGH GLUCOSE AND INSULIN ON VASORELAXATION TO
ANANDAMIDE
W.-S. Vanessa Ho
44 THE ENDOCANNABINOID ANANDAMIDE MEDIATES HYPOXIC PULMONARY
VASOCONSTRICTION VIA FATTY ACID AMIDE HYDROLASE (FAAH)
METABOLIZATION PRODUCTS
D. Wenzel , M. Matthey, R. Buchalla, C. Schwitter, B. Lutz, A. Zimmer, B. K. Fleischmann
45 STRATEGIC LOCALIZATION OF TRPV1 EXPRESSING CELLS IN THE BRAIN
VASCULAR SYSTEM
M. Tauchi and R. Kollmar
46 SINGLE DOSE ADMINISTRATION OF CANNABIDIOL AFTER BRAIN HYPOXIA-
ISCHEMIA AFFORDS LONG-LASTING NEUROPROTECTION IN NEWBORN RATS
Pazos MR, Cinquina V, Gomez A, Layunta R, Mohamed N, Martinez-Orgado J.
47 ENDOCANNABINOID CONTENT IN FETAL BOVINE SERA - UNEXPECTED
EFFECTS ON MONONUCLEAR CELLS AND OSTEOCLASTOGENESIS
J. Marazzi , J. Kleyer, J. M. Viveros Paredes, J. Gertsch
48 OSTEOCLASTOGENESIS INHIBITION BY A NOVEL CLASS OF BIPHENYL-TYPE CANNABINOID CB2 RECEPTOR INVERSE AGONISTS
J. M. Viveros Paredes, W. Schuehly, J. Kleyer, A. Huefner, S. Anavi-Goffer, S. Raduner, K.-H. Altmann and J. Gertsch
49 DO CB1 CANNABINOID RECEPTORS REGULATE INSULIN SIGNALLING IN RAT PRIMARY SKELETAL MUSCLE CELLS?
M. Haddad , K. Tsintzas, S.P.H. Alexander and A.J. Bennett
50 CB1 CANNABINOID RECEPTOR ANTAGONISM INHIBITS BALLOON-INDUCED NEOINTIMA FORMATION IN ATHEROSCLEROTIC MICE
F. Molica , F. Burger, C. M. Matter, A. Thomas, C. Staub, A. Zimmer, B. Cravatt, P. Pacher, S. Steffens
51 THE ENDOCANNABINOID SYSTEM SHOWS DIFFERENT ALTERATIONS IN IN
VITRO AND IN VIVO MODELS OF HUNTINGTON'S DISEASE
M. Maccarrone, M. Bari, N. Battista, M. Valenza, M. Malaponti, G. Catanzaro, C. Di Pancrazio, N. Mastrangelo, D. Centonze, A. Finazzi-Agro, E. Cattaneo and S. Oddi
52 DISEASE-MODIFYING EFFECTS OF WIN55.212-2 IN A MODEL OF MULTIPLE
SCLEROSIS IN MICE: ROLE OF CB1 AND CB2 RECEPTORS
E. de Lago , M. Moreno-Martet, C. Rodrfguez-Cueto, C. Palomo-Garo, C. Garcia, M. Gomez-Ruiz, J. A. Ramos and J. Fernandez-Ruiz
53 EFFECTS OF CANNABIS USE ON SOME IMMUNE PARAMETERS IN PATIENTS
WITH MULTIPLE SCLEROSIS
M. Sexton and N. Stella
54 CANNABIDIOL, NON-PSYCHOACTIVE CANNABINOID, AMELIORATES CLINICAL SYMPTOMS AND DECREASES MICROGLIAL ACTIVATION IN MOG-TREATED MICE
E. Kozela , N. Lev, A. Juknat, M. Pietr, N. Rimmerman, R. Levy, Z. Vogel
55 A NOVEL 3D MODEL OF THE HUMAN CANNABINOID RECEPTOR 2 IN ITS ACTIVE STATE HELPS TO DEVELOP NEW RADIOTRACERS FOR POSITRON EMISSION TOMOGRAPHY (PET)
R. Gunther , W. Deuther-Conrad, S. Fischer, T. Ruhl, J. Steinbach, P. Brust
56 18 FLUORINE-LABELED NITROGEN HETEROCYCLIC DERIVATIVES AS NEW
CANDIDATE FOR CANNABINOID CB2 RECEPTOR PET IMAGING
F. Castelli , G. Saccomanni, S. Bertini, S. Del Carlo, V. Di Marzo, V. Lucchesi, C. Manera, G.
Pascali, P. Salvadori, M. Macchia
57 DEVELOPMENT OF AN ULTRA SENSITIVE LC-MS/MS METHOD FOR THE
SIMULTANEOUS DETERMINATION OF A9-TETRAHYDROCANNABINOL AND ONE OF ITS MAJOR METABOLITES A9-(11-OH) TETRAHYDROCANNABINOL IN HUMAN PLASMA
M. Boterman , T. Beumer, F. Oostebring, A. Meijer and E. Oosting
58 DEVELOPMENT, VALIDATION AND USE OF A LC-MS/MS METHOD TO ASSAY
FAAH ACTIVITY IN BIOLOGICAL SAMPLES
C. Rakers , A. A. Zoerner, S. Batkai, S. Engeli, J. Jordan, D. Tsikas
59 A NEW TLC DENSITOMETRY METHOD IN A KIT-FORMAT FOR COMPLETE
SEPARATION AND VISUALISATION OF ALL CANNABINOIDS IN CANNABIS
SPECIES
R.J. Glas
60 INTESTINAL N-ACYLETHANOLAMINE LEVELS ARE DOWN-REGULATED IN BOTH MICE AND RATS BY SENSING OF DIETARY FAT
T. A. Diep , A. N. Madsen, N. Wellner, B. Hoist and H. S. Hansen
61 CIRCADIAN RHYTHM OF BLOOD ENDOCANNABINOIDS - IS FOOD INTAKE THE KEY TRIGGER?
M. May , S. Batkai, A. A. Zoerner, D. Tsikas, J. Jordan, S. Engeli
62 STUDIES ON THE ANORECTIC EFFECT OF N-ACYLPHOSPHATIDYLETHANO-
LAMINE AND PHOSPHATIDYLETHANOLAMINE IN MICE
N. Wellner , K. Tsuboi, A. N. Madsen, B. Hoist, T. A. Diep, M. Nakao, A. Tokumura, M. P. Burns, D. G. Deutsch, N. Ueda and H. S. Hansen
63 EFFECTS OF CHRONIC ADMINISTRATION OF CANNABINOID RECEPTOR
INVERSE AGONIST (AM 251) ON THE FOOD INTAKE, BODY WEIGHT GAIN AND
OXYGEN CONSUMPTION IN OBESE ZUCKER RATS
I. Merroun , J. M. Porres, G. Urbano, P. Aranda, J. Llopis, M. Errami and M. Lopez-Jurado
64 METABOLIC FINGERPRINTING OF CANNABIS SATIVA L, CANNABINOIDS AND TERPENOIDS FOR CHEMOTAXONOMIC AND DRUG STANDARDIZATION
PURPOSES
J. T. Fischedick , A. Hazekamp, T. Erkelens, Y. H. Choi, R. Verpoorte
65 CANNABINOID RECEPTOR 1 IN HODGKIN LYMPHOMA AND B-CELL NON-HODGKIN LYMPHOMA ENTITIES: EXPRESSION AND FUNCTIONAL RELEVANCE FOR SURVIVAL OF TUMOR CELLS
A. H. Benz , C. Renne, M. Koch, E. Maronde, S. Kallendrusch, B. Rengstl, S. Newrzela, S.
Hartmann, M.-L. Hansmann and F. Dehghani
66 DEVELOPMENT OF CB2 SELECTIVE CANNABINOID RECEPTOR LIGANDS AS
POTENTIAL ANTITUMOR AGENTS
V. Lucchesi , F. Castelli, C. Manera, S. Bertini, S. Del Carlo, A. Ligresti, A. M. Malfitano, G. Saccomanni, V. Di Marzo, M. Bifulco, M. Macchia
67 BASALIOMA TREATMENT WITH INTRATUMORAL INJECTIONS OF A CANNABIS-OIL EXTRACT: A SINGLE-CASE STUDY
J. Pedraza-Valiente
68 IMPROVEMENT OF CLONAL PROPAGATION OF CANNABIS SATIVA L. FOR
PHARMACEUTICAL PRODUCTION
S. Beguerie , S. Casano, G. Grassi
69 CLONING OF PHARMACEUTICAL CANNABIS THROUGH AN AEROPONIC
PROPAGATION SYSTEM
S. Beguerie , S. Casano, G. Grassi
70 ESTIMATION OF USABLE BIOMASS YIELD OF OUTDOOR CULTIVATED CANNABIS SATIVA L. PLANTS
Z. Mehmedic , S. Chandra, H. Lata, I. A. Khan and M. A. ElSohly
71 A QUESTIONNAIRE SURVEY OF PATIENTS PRESCRIBED SATIVEX AS
UNLICENSED MEDICINE
Notcutt, W.
72 GLYCINE RECEPTORS, A NEW TARGET FOR MEDICAL MARIJUANA
L. Zhang and W. Xiong
73 USE OF MEDICINAL CANNABIS IN THE NETHERLANDS
L. Wiinkoop , A. Hazekamp, R. Heerdink
74 MEDICAL CANNABIS USE IN POST-TRAUMATIC STRESS DISORDER: A
NATURALISTIC OBSERVATIONAL STUDY
75 PSYCHOSOCIAL STRESS MODULATES CIRCULATING ANANDAMIDE AND
OTHER N-ACYLETHANOLAMINES IN HEALTHY HUMANS
A. Dluqos , E. Childs, K. Stuhr, C. Hillard, H. de Wit
76 THE EFFECT OF CANNABIS INTOXICATION ON EGO EQUILIBRIUM:
INVESTIGATING THE ACUTE DEVELOPMENTAL IMPACT OF AN ALTERED STATE OF CONSCIOUSNESS
M. Metzqer
77 THE SOCIAL AND BIOETHICAL ASPECTS OF USE OF MEDICINAL CANNABIS IN CROATIA
M. Gold , S. Kantar, K. Svrznjak
78 EVALUATION OF A NEW PLATFORM TO ADMINISTER CANNABINOIDS BY
INHALING: MINIVAP® PORTABLE VAPORIZER
J. Fernandez , A. Hazehamp
79 INTOXICATIONS FOLLOWING RECREATIONAL USE OF HERBAL PRODUCTS
CONTAINING SYNTHETIC CANNABINOIDS
Bela Szabo , Volker Auwarter, Stefan Kneisel and Maren Hermanns-Clausen
Abstract book online:
- Internet Archive: http://www.archive.org/details/CannabinoidConference2011
this blog is awesome!
ReplyDelete